Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	7.07M 21.54M 6.2M 5.86M 5.34M 9.99M 677M 10.06M 70.09M 27.15M 346M 26.53M 25.96M 1.11B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	7.07M 21.54M 6.2M 5.86M 5.34M 9.99M 677M 10.06M 70.09M 27.15M 346M 26.53M 25.96M 1.11B	EV / Sales 2026 *	4.76x	EV / Sales 2027 *	2.72x
Free-Float	72.14%	Yield 2026 *	-	Yield 2027 *	-

09-11	L.I.A. Pure Capital Intends to Commence a Special Tender Offer to Evogene	CI
09-04	Evogene Ltd. Approves Board Appointments	CI
08-28	L.I.A. Pure Capital Issues Response to Evogene	CI
08-25	Institutional Shareholder Services and Glass Lewis Makes Recommendations to Shareholders	CI
08-18	Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026
08-18	Evogene Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-17	Freightos Names Yaron Eldad as Chief Financial Officer	MT
07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/12/20	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

08-31	Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward	PR
08-25	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees	PR
08-18	Evogene Reports Second Quarter and First Half 2026 Financial Results	PR
08-18	Evogene : Reports Second Quarter and First Half 2026 Financial Results	PU
08-18	Evogene: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	30/11/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	31/12/2021

Evogene Ltd. Share Price TEL AVIV STOCK EXCHANGE

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Latest news: Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Managers and Directors: Evogene Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	02/06/2010
Sarit Firon CHM	Chairman	60	31/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	-1.98%	-7.28%	-	-	7.07M
LONZA GROUP AG	-0.14%	+4.33%	+9.00%	+31.64%	47.97B
IQVIA HOLDINGS INC.	-1.69%	+1.48%	+50.57%	+34.53%	44.5B
REVOLUTION MEDICINES, INC.	+2.56%	+7.34%	+366.69%	+608.26%	43.93B
BEONE MEDICINES AG	+0.24%	+2.85%	+10.67%	+94.47%	41.03B
CELLTRION, INC.	-0.62%	-1.11%	+4.65%	+48.91%	29.85B
MEDPACE HOLDINGS, INC.	-0.28%	+1.07%	+24.58%	+155.58%	17.27B
TEMPUS AI, INC.	+3.37%	+9.21%	+8.32%	-	15.34B
EUROFINS SCIENTIFIC SE	-0.46%	+1.20%	+26.90%	+42.21%	15.3B
ASCENDIS PHARMA A/S	-2.21%	-4.70%	-	-	14.82B
Average	-0.12%	+2.35%	+62.67%	+145.08%	30B
Weighted average by Cap.	+0.11%	+2.86%	+79.67%	+160.28%

	2026 *	2027 *
Net sales	1.48M 4.52M 1.3M 1.23M 1.12M 2.1M 142M 2.11M 14.72M 5.7M 72.66M 5.57M 5.45M 234M	2.6M 7.93M 2.28M 2.15M 1.96M 3.68M 249M 3.7M 25.79M 9.99M 127M 9.76M 9.55M 409M
Net income	-16.69M -50.87M -14.64M -13.83M -12.6M -23.59M -1.6B -23.76M -165M -64.1M -817M -62.65M -61.3M -2.63B	-13.92M -42.42M -12.21M -11.53M -10.51M -19.67M -1.33B -19.81M -138M -53.45M -681M -52.25M -51.12M -2.19B
Net Debt	-	-